Anyone in the world
Dr Pierre Delanaye Posted from EDTA Paris on OLA French and translated:
First "summary" of EDTA for those who do not have the opportunityto attend.
Study of the session "Late Clinical Trial"
The study was conducted in Okinawa. It is named OCTOPUS and is presented by Dr. Iseki.
The study concerns the interest of olmesartan in patientsundergoing hemodialysis. The defintion used for the HTA is a voltage higher than 140/90. Subjects are randomized and followed for 3.6 years. Are included hemodialysis patients from 20 to 79 years. Excluded are patients receiving ACE inhibitors or ARBs, thesevere hypertension (> 200/100), hypotension in dialysis frequentdialysis vintage within a month.
235 subjects in the olmesartan group and 234 in the control group.
Patients are randomized with the following characteristics("rounded"): 60 years, 88 months of dialysis (!), 32% had diabetes,BMI 24, KT / V 1.15, systolic BP 160 mmHg, diastolic BP to 80 mm Hg
BP was controlled identically in both groups but overall systolic BPremains above 140 mmHg.
The authors observed no difference in mortality nor in theircombined primary endpoint (cardiovascular endpoints: Infar, stroke,unstable angina, heart failure requiring hospitalization). Side effects are also identical (including hyperkalemia).
Limitations of the study: no data on the water status which is arelatively important limitation, selection of patients likely the "best"patients, particularly given the number of years already spent indialysis, very low number of events (even for Japan), for examplemortality of 4.7% per year and combined endpoint of 9.1% per year.
Another negative study dialysed patients ...
[ Modified: Thursday, 1 January 1970, 1:00 AM ]